Table 2 |
|||||||
| Clinicopathological profiles of endometrial intraepithelial carcinomas | |||||||
| Case | EIC location | Immunohistochemistry | FIGO stage | Outcome (periode) | |||
| P53a | MIB-1b | ERc | PgRd | ||||
| 1 | polyph | + | 30 | + | + | IA | DFi (66 months) |
| 2 | polyp & endometrium | + | 60 | - | - | IA | DF (65 months) |
| 3f | polyp & endometrium | + | 35 | - | - | IA | DF (36 months) |
| 4 | polyp | + | 30 | - | - | IA | DF (30 months) |
| 5 | polyph & endometrium | + | 45 | - | + | IA | DF (39 months) |
| 6 | polyp | + | 25 | - | - | IA | DF (39 months) |
| 7 g | polyp | - | 30 | - | - | IA | DODj (44 months) |
| 8 | polyph & endometrium | - | 70 | - | - | IA | DF (12 months) |
a:+, strongly positive cells more than 80%.
b: index of positive cells(%), c: +, positive cells more than 80%.
d: +, positive cells more than 80%.
e: since initial diagnosis.
f: history of breast cancer with Tamoxifen administration.
g: autopsy performed.
h: with stromal invasion, i: disease free, j: death on disease.
Yasuda et al. Diagnostic Pathology 2013 8:25 doi:10.1186/1746-1596-8-25
